Cardinal Healthの空売り状況は、投資家がCardinal Healthの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Cardinal Health (NYSE:CAH) 株価情報, 空売り情報

Cardinal Health

Cardinal Health is one of three leading pharmaceutical wholesalers in the us, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the us pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Earnings

Equities

News

Futures

Previews

Economics

Federal Reserve

Pre-Market Outlook

Markets

Movers

Trading Ideas

$BTC

CSCO

GOOGL

HNHPF

LITE

NVDA

PFGC

PTON

８月３日（水）午前８時３０分（米国東部時間）に公表される消費者物価指数（CPI）速報に先駆け、主要指数先物は神経質な値動きを示している。債券利回りは消費者物価指数発表前に低下している。今回の報告が価格圧力の緩和が続いていることを確認した場合、米連邦準備制度理事会（FRB）は利上げを余儀なくされる可能性がある。経済学者やストラテジストは、FRB総裁のジェローム・パウエル氏が今月末に予定されている＜ジャクソンホール・シンポジウム＞で、利上げ見通しについてさらに明確な見解を示すと予想している。

ウォール・ストリート　主要先物指数が反応

Cardinal Health Inc

CARRIER ALLIANCE HLDGS by Carrier Alliance Holdings, Inc.

Carrier Alliance Holdings Inc

CELESTIAL ASIA SECS NEW by Celestial Asia Secs Holdings Ltd.

Celestial Asia Securities Holdings Ltd

Caro Holdings Inc

EVOLUTION MINING LTD ORD by Evolution Mining Ltd.

Evolution Mining Ltd

Cardinal Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) short percent of float has fallen 26.84% since its last report. The company recently reported that it has 4.22 million shares sold short, which is 2.29% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cardinal Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736873110_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cardinal Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cardinal Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cardinal Health's peer group average for short interest as a percentage of float is 4.55%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(CAH) - Analyzing Cardinal Health's Short Interest

Cardinal Health, Inc. (the "Company") is providing an update to its previously announced expectations for non-GAAP diluted earnings per share ("non-GAAP EPS") for fiscal year 2025. The Company now expects fiscal year 2025 non-GAAP EPS to be toward the high end of its previously provided range of $7.75 to $7.90, primarily driven by continued strength within the Pharmaceutical and Specialty Solutions segment.

Guidance

Cardinal Health Expects FY25 Adj EPS To Be Toward Higher End Of $7.75-$7.90 Vs $7.84 Est

Citigroup analyst Daniel Grosslight maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Neutral and raises the price target from $120 to $129.

Price Target

Analyst Ratings

Citigroup Maintains Neutral on Cardinal Health, Raises Price Target to $129

Editor&#8217;s Note: The story has been updated for improved clarity and readability.
On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer weighed in on stocks brought up by viewers, highlighting risks and opportunities in the market.
<h3 class="wp-block-heading">High Valuations Prompt Caution</h3>
Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) has climbed significantly, prompting Cramer to caution, &#8220;up too much&#8230; You got to let it come down.&#8221; JMP Securities' Ronald Josey echoed similar concerns, maintaining a Market Outperform rating and raising the price target from $40 to $60 on Nov. 22.
<h3 class="wp-block-heading">Healthcare Stocks In Focus</h3>
Cencora, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) could &#8220;go lower,&#8221; Cramer said, preferring Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) instead. Cencora has been expanding its portfolio, completing its acquisition of Retina Consultants of America on Jan. 2. The move strengthens its position in specialized healthcare.
For Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Cramer advised caution, saying he would be &#8220;careful&#8221; with the stock. The company recently reported Phase 3 trial results for its <a href="https://www.benzinga.com/government/regulations/24/12/42623343/exclusive-weight-loss-market-experts-scoop-up-novo-nordisk-stock-after-worst-drop-since-2002-following-drug-trial-miss">CagriSema combination therap</a>y, which showed promising outcomes but the stock is down over 22% in the past month.
<h3 class="wp-block-heading">GLP-1 Impact on Consumer Staples</h3>
Cramer pointed out challenges for PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>), saying it's in the &#8220;crosshairs of the GLP-1 situation.&#8221; Despite this, Piper Sandler's Mike Lavery initiated coverage on Jan. 7 with an Overweight rating and a $171 price target, reflecting optimism for PepsiCo's resilience in response to shifting consumer trends.
Price Action:
<ul>
<li>Novo Nordisk shares fell 2% to settle at $83.34 on Tuesday.</li>
<li>PepsiCo shares fell 0.6% to close at $145.40 during the session.</li>
<li>Cencora shares gained 2.3% to settle at $234.24.</li>
<li>Lemonade shares fell 6.3% to settle at $36.14 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42846607/bank-of-new-york-mellon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

LMND

Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower (UPDATED)

TD Cowen analyst Charles Rhyee upgrades Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Hold to Buy and raises the price target from $130 to $144.

Upgrades

TD Cowen Upgrades Cardinal Health to Buy, Raises Price Target to $144

BofA Securities predicts that headline risks affecting the Healthcare Tech &amp; Distribution sector in 2024 will likely continue in 2025.
Key areas of concern include pharmacy benefit managers (PBMs), retail pharmacies, distributors, fertility benefits, and direct-to-consumer (D2C) pharmacies.
While regulatory pressure on PBMs is expected to persist, the analyst believes this will mainly impact profit margins and growth rates rather than lead to major changes in the business model.
Potential policy shifts under the next administration could involve adjustments to the Inflation Reduction Act, expanded access to health savings accounts (HSAs), and increased support for fertility benefits.
BofA upgraded Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from <a target="_blank" href="https://www.benzinga.com/quote/CAH/analyst-ratings" rel="noreferrer noopener">Neutral to Buy</a>. The analyst notes Cardinal Health&#8217;s core pharmaceutical segment is growing faster than its competitors, with this trend expected to strengthen in the coming year.
Also Raed: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41684029/cardinal-health-raises-2025-profit-outlook-again-helped-by-strong-drug-distribution-business" rel="noreferrer noopener">Cardinal Health Raises 2025 Profit Outlook Again, Helped By Strong Drug Distribution Business</a>
The company is benefiting from a unique advantage in its pharmacy benefit management (PBM) business, which could add 2-3 percentage points to earnings per share growth through fiscal 2026.
Despite its stronger growth potential, Cardinal&#8217;s stock is trading at a notable discount compared to McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), but this gap is likely to close or reverse within the next year.
BofA has also upgraded Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) from <a target="_blank" href="https://www.benzinga.com/quote/HSIC/analyst-ratings" rel="noreferrer noopener">Underperform to Buy</a> and raised the price target from $69 to $84, recognizing it as a top-tier dental business poised for long-term earnings growth.
The company is recovering from last year&#8217;s cybersecurity incident, which should <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41752173/henry-schein-q3-earnings-sees-recovery-from-cyber-incident-says-dental-equipment-business-shows-sta" rel="noreferrer noopener">boost reported figures</a>.
With these challenges behind it and expectations now more realistic, the analyst writes Henry Schein offers a strong opportunity to benefit from a recovering dental market.
The company could see additional upside in the medium to long term, driven by a shift toward private-label products and a growing focus on specialty services. The analyst notes the price target of $84 is reasonable given its position at a market low.
Price Action: At the last check Tuesday, CAH stock was up 0.61% at $120.36, and HSIC stock was down 0.08% at $71.70.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42853126/phillips-66-powers-up-with-22-billion-deal-for-epic-y-grades-ngl-business" target="_blank" rel="noreferrer noopener">Phillips 66 Powers Up With $2.2 Billion Deal For EPIC Y-Grade&#8217;s NGL Business</a></li>
</ul>
Photo by Casimiro PT via Shutterstock

Analyst Color

Large Cap

Health Care

General

HSIC

Headline Risks Affecting Healthcare Tech & Distribution Sector Will Likely Continue in 2025: BofA Analyst

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group analyst Elizabeth Anderson upgraded the rating for Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from In-Line to Outperform and maintained the price target of $140. Cardinal Health shares closed at $119.63 on Monday. <a href="https://www.benzinga.com/quote/CAH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan analyst Kenneth Worthington upgraded Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from Underweight to Neutral and boosted the price target from $20 to $43. Robinhood shares closed at $42.71 on Monday. <a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc analyst Matthew Gillmor upgraded the rating for Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) from Sector Weight to Overweight and announced a $70 price target. Acadia Healthcare shares closed at $44.85 on Monday. <a href="https://www.benzinga.com/quote/ACHC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Aneesha Sherman upgraded the rating for Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) from Market Perform to Outperform. Lululemon shares closed at $395.31 on Monday. <a href="https://www.benzinga.com/quote/LULU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Michael Turrin upgraded Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from Equal-Weight to Overweight and raised the price target from $150 to $200. Snowflake shares closed at $163.08 on Monday. <a href="https://www.benzinga.com/quote/SNOW/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying HOOD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="603" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-1024x603.png" alt="" class="wp-image-721866" style="width:586px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-1024x603.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-768x452.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34.png 1155w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

ACHC

HOOD

LULU

SNOW

This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Evercore ISI Group analyst Elizabeth Anderson upgrades Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from In-Line to Outperform and maintains the price target from $140 to $140.

Evercore ISI Group Upgrades Cardinal Health to Outperform, Maintains Price Target to $140

B of A Securities analyst Michael Cherny upgrades Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Neutral to Buy and raises the price target from $132 to $145.

B of A Securities Upgrades Cardinal Health to Buy, Raises Price Target to $145

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $127 to $136.

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $136

<a href="https://www.youtube.com/watch?v=fjFI9jPVh-A" title="https://www.youtube.com/watch?v=fjFI9jPVh-A">https://www.youtube.com/watch?v=fjFI9jPVh-A</a>

Biotech

Macro Economic Events

Global

President-Elect Donald J. Trump Says 'We're Going To Knock Out The Middlemen' Who Are Keeping Drug Prices High

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wolfe Research analyst Darrin Peller upgraded the rating for PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) from Peer Perform to Outperform and announced a $107 price target. PayPal shares closed at $89.40 on Thursday. See how other analysts view this stock.</li>
<li>B of A Securities analyst Tal Liani upgraded Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) from Neutral to Buy and raised the price target from $70 to $95. Ciena shares closed at $84.52 on Thursday. <a href="https://www.benzinga.com/quote/CIEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Kyle Peterson upgraded Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) from Hold to Buy and announced a $100 price target. Upstart shares closed at $77.08 on Thursday. See how other analysts view this stock.</li>
<li>UBS analyst A.J. Rice upgraded the rating for Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Neutral to Buy and increased the price target from $79 to $80. Centene shares closed at $58.00 on Thursday. <a href="https://www.benzinga.com/quote/CNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Stephen Baxter upgraded the rating for Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Underweight to Equal-Weight and raised the price target from $101 to $127. Cardinal Health shares closed at $117.46 on Thursday. <a href="https://www.benzinga.com/quote/CAH/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PYPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="622" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-1024x622.png" alt="" class="wp-image-691544" style="width:605px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-1024x622.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-768x466.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a></li>
</ul>

CIEN

PYPL

UPST

This PayPal Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wells Fargo analyst Stephen Baxter upgrades Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Underweight to Equal-Weight and raises the price target from $101 to $127.

Wells Fargo Upgrades Cardinal Health to Equal-Weight, Raises Price Target to $127

TTOO

T2 Biosystems To License Proprietary Technology For Direct-From-Whole-Blood Sepsis Pathogen Detection, Aiming To Generate Non-Dilutive Capital, Create Royalty Revenue Streams, And Broaden Adoption Of FDA-Cleared Diagnostics Powered By T2MR Detection And Adaptable Sample Processing Technology

FDA Says Cardinal Health Removes Some Monoject U-100 mL Insulin Syringe Luer Lock With Tip Cap Soft Packs

Cardinal Health Announced The U.S. Launch Of Its Kendall SCD SmartFlow Compression System, The Next Generation Of The Kendall Compression Series Offering An Enhanced Clinician And Patient Experience

Cardinal Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) short percent of float has fallen 26.42% since its last report. The company recently reported that it has 5.50 million shares sold short, which is 2.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.61 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cardinal Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732035620_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cardinal Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cardinal Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cardinal Health's peer group average for short interest as a percentage of float is 5.81%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Cardinal Health's Recent Short Interest

<ul>
<li>Acquisition of a majority stake in GI Alliance, the country's leading&nbsp;gastroenterology management services organization, to accelerate Cardinal Health's multi-specialty growth strategy</li>
<li>Acquisition of the Advanced Diabetes Supply Group, a leading national direct-to-patient provider of diabetes medical supplies, to accelerate Cardinal Health's at-Home Solutions growth strategy</li>
<li>Company announces plan to hold Investor Day in June 2025</li>
</ul>
Cardinal Health will acquire a majority stake in GI Alliance (GIA), the country's leading gastroenterology (GI) management services organization (MSO), from a combination of GIA physician owners and funds managed by affiliates of Apollo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>). Cardinal Health will purchase its majority stake for approximately $2.8 billion in cash, which will represent 71% ownership. GIA will operate as a platform within Cardinal Health's Pharmaceutical and Specialty Solutions segment. &nbsp;
Cardinal Health will also acquire the Advanced Diabetes Supply Group (ADSG), one of the country's leading diabetic medical supplies providers, for approximately $1.1 billion in cash. ADSG will merge with Cardinal Health's at-Home Solutions business.

Reported Earlier, Cardinal Health Accelerates Strategic Growth With $3.9B GI Alliance Acquisition And $1.1B Advanced Diabetes Supply Group Buyout

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $119 to $127.

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $127

Deutsche Bank analyst George Hill maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Hold and raises the price target from $119 to $124.

Deutsche Bank Maintains Hold on Cardinal Health, Raises Price Target to $124

Cardinal Health expects profit for FY 2025 near top end of guidance

Cardinal Health ( ($CAH) ) has issued an announcement. Cardinal Health updated its non-GAAP diluted earnings per share expectations for fiscal year...

Cardinal Health Raises 2025 Earnings Forecast Expectations

Cardinal Health (CAH) announced construction is underway on a new distribution center in Fort Worth, Texas, which will support its at-Home Solution...

Cardinal Health to open new distribution center in Fort Worth, Texas

Cardinal Health, Inc. (CAH) CEO Jason Hollar presents at J.P. Morgan Healthcare Conference (Transcript)

Mizuho Securities analyst Steven Valiquette has maintained their bullish stance on CAH stock, giving a Buy rating on January 10. Steven Valiquette ...

Cardinal Health's Strong Pharma and Specialty Growth Justifies Buy Rating and Raised EPS Guidance

Bank of America Securities analyst Allen Lutz maintained a Buy rating on Cardinal Health (CAH – Research Report) yesterday and set a price target o...

Cardinal Health's Strong Pharmaceutical Performance and Strategic Growth Drive Buy Rating

Wells Fargo analyst Stephen Baxter maintained a Hold rating on Cardinal Health (CAH – Research Report) yesterday and set a price target of $127.00....

Balanced Outlook on Cardinal Health: Hold Rating Reflects Limited Upside Despite Strong Pharma Performance

Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on Cardinal Health (CAH – Research Report) yesterday and set a price target of ...

Evercore ISI Reaffirms Their Buy Rating on Cardinal Health (CAH)

Leerink Partners analyst Michael Cherny has maintained their bullish stance on CAH stock, giving a Buy rating on January 15. Michael Cherny has giv...

Cardinal Health's Strong Future Prospects and Upward Guidance Drive Buy Rating

UnitedHealth CEO: American healthcare needs to be "less complex and less confusing'

Press Releases

Cardinal Health Reports First Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook

Dividends

Cardinal Health Board of Directors Approves Quarterly Dividend

Cardinal Health announces two strategic additions to its portfolio

GI Alliance to Partner with Cardinal Health Creating a Scaled Multi-Specialty Managed-Services Platform to Benefit Physicians and Patients

Court Square Capital Partners Announces Sale of Advanced Diabetes Supply Group

Cardinal Health launches Kendall SCD SmartFlow™ Compression System

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

Comments

Cardinal Health

空売り

Cardinal Health (NYSE:CAH) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル